[1] Schafer EJ, Laversanne M, Sung H, et al.Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update[J]. Eur Urol, 2025, 87(3): 302-313. [2] 赛麦提喀日·阿布都巴日, 梅玉洁, 陶宁, 等. 前列腺癌的危险因素及列线图预测模型的构建[J]. 新疆医科大学学报, 2022, 45(8): 911-917. [3] Nahar B, Ajami T, Williams A, et al.Survival Outcomes and Recurrence Patterns Following Focal High-intensity Focused Ultrasound Treatment for Localized Prostate Cancer: Insights on Patient Selection and Lessons Learned[J]. Eur Urol Focus, 2024. DOI: doi.org/10.1016/j.euf.2024.11.005. [4] 礼彦侠, 徐绍和, 毛春莹, 等. 辽宁省城市前列腺癌患者10年生存率及影响因素分析[J]. 中国卫生统计, 2022, 39(6): 908-911. [5] Osman NMM, Kader MA, Nasr TAELA, et al.The Role of Diffusion-Weighted MRI and Apparent Diffusion Coefficient in Assessment of Diabetic Kidney Disease: Preliminary Experience Study[J]. Int J Nephrol Renovasc Dis, 2021, 14: 1-10. [6] Pacini M, Zucchi A, Morganti R, et al.Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy[J]. Sci Rep, 2025, 15(1): 4310. [7] 李冠男, 李林. PET/CT在前列腺癌放疗规划中的应用[J]. 中华核医学与分子影像杂志, 2020, 40(9): 567-576. [8] 齐来雪, 史学权, 张维春, 等. 磁共振弥散加权成像多弥散敏感因子及T2WI诊断前列腺癌的价值分析[J]. 中国医学装备, 2020, 17(9): 73-76. [9] 段云, 康钰龄, 郑虹蕾, 等. fPSA%、PSAD、proGRP水平对前列腺癌及骨转移的诊断价值[J]. 西部医学, 2021, 33(4): 605-610. [10] 中国抗癌协会泌尿男生殖系肿瘤专业委员会微创学组. 中国前列腺癌外科治疗专家共识[J]. 中华外科杂志, 2017, 55(10): 721-724. [11] 李方龙, 邱建宏, 张世睿, 等. 不同前列腺体积计算方式对前列腺特异性抗原密度诊断前列腺癌的影响[J]. 现代泌尿外科杂志, 2020, 25(9): 810-812. [12] Jung G, Song B, Ahn H, et al.Oncological outcomes after radical prostatectomy of localized prostate cancer: stratified by magnetic resonance imaging and risk classification[J]. Prostate Int, 2024, 12(4): 224-230. [13] Braga I, Gonçalves-Monteiro S, Calisto R, et al.Real-world retrospective study of early-stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study[J]. Oncol Lett, 2024, 28(2): 362. [14] Hoeh B, Preisser F, Zattoni F, et al.Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval[J]. Eur Urol Oncol, 2025, 8(2): 372-379. [15] 崔强, 王凡, 程华才, 等. 不同b值ADC对前列腺癌患者术后Gleason评分的预测效果[J]. 中南医学科学杂志, 2024, 52(4): 669-672. [16] Kim DHS, Sonni I, Grogan T, et al.Quantitative 3-T Multiparametric MRI Parameters as Predictors of Aggressive Prostate Cancer[J]. Radiol Imaging Cancer, 2025, 7(1): e240011. [17] 黄晓华, 孙蕾, 王雨, 等. 3.0T常规MRI联合多b值DWI在前列腺癌诊断中的价值[J]. 中国CT和MRI杂志, 2024, 22(6): 124-126. [18] 刘武宗. MRI表观扩散系数与前列腺癌临床病理特征的相关性分析及预后价值[J]. 生命科学仪器, 2022, 20(5): 75-81. [19] Nakai H, Takahashi H, LeGout JD, et al. Prostate Cancer Risk Prediction Model Using Clinical and Magnetic Resonance Imaging-Related Findings: Impact of Combining Lesions' Locations and Apparent Diffusion Coefficient Values[J]. J Comput Assist Tomogr, 2025, 49(2): 247-257. [20] Luo L, Wang R, Bai L, et al.The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone[J]. Br J Cancer, 2025, 132(3): 253-258. [21] Khalid SY, Waraich TA, Elamin A.Evaluating the Diagnostic Accuracy of MRI-Derived Prostate-Specific Antigen (PSA) Density in Prostate Cancer Detection and its Association With Tumor Aggressiveness[J]. Cureus, 2024, 16(11): e74368. [22] Ayranci A, Caglar U, Yazili HB, et al.PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI-RADS 3 Lesions[J]. Prostate, 2025, 85(4): 385-390. [23] 汪蕾, 肖峻, 陶陶, 等. 双参数磁共振成像-经直肠超声引导靶向穿刺与前列腺特异性抗原或前列腺特异性抗原密度组合对前列腺癌诊断价值的研究[J]. 中国临床保健杂志, 2022, 25(3): 402-406. [24] 李方龙, 杜春花, 张荣心, 等. 不同路径超声测量前列腺体积对PSAD诊断前列腺癌影响的研究[J]. 现代泌尿生殖肿瘤杂志, 2022, 14(5): 288-292. [25] 黄松, 盛伟华, 李烨, 等. MRI扩散加权定量参数ADC值与前列腺癌Gleason评分及血清PSA相关性分析[J]. 中国CT和MRI杂志, 2022, 20(12): 124-126. |